Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration

Related

• 

  Fluctuations in Central Foveal Thickness and Vision Outcomes With Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

  Veeral S. Sheth, MD, MBA, FASRS, FACS

  Annual Meeting Talks

  2020

• 

  AMD Neovascular Expert Panel

  Robert L. Avery, MD

  Nizar S Abdelfattah, M.D.

  Nancy M. Holekamp, MD, FASRS

  Peter K. Kaiser, MD FASRS

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2016

• 

  Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Should Baseline Characteristics Affect Choice of Treatment?

  Susan B. Bressler, MD, FASRS

  Annual Meeting Talks

  2018